Given the morphological variability and high number of palliative prostate cancer lesions under [177Lu]Lu-PSMA therapy - often greater than in melanoma or pulmonary cases - this represents a significant advancement, particularly as Rafael-Palou et al. also used a Siamese architecture [21]. The gene discussed is FOLH1; the disease is melanoma.